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Abstract 
The benefits of improved treatments for cystic fibrosis (CF) depend on optimal adherence 
which remains problematic, particularly to aerosol therapy.  In this study, we explored the 
process of adhering to aerosol therapy from the perspective of both adolescents with CF and 
their parents.  Interviews were conducted individually with six adolescents and six parents, 
informed by accurate adherence data from an electronically chipped, aerosol device.  
Interview-transcripts from audio-recordings were analyzed using Grounded Theory Method 
(GTM).  Major themes revealed differences in perspective between parent and adolescent, 
with this relationship mediating the cognitive and emotional processes that play a significant 
role in adherence behavior.  These processes are further influenced by interactions with the 
aerosol therapy treatment regimen, device characteristics and the context in which adherence 
is taking place.  Parents and adolescents have different views of treatment and how to manage 
it.  Both need to be addressed if optimal adherence is to be achieved. 
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Background 
Cystic fibrosis (CF) is a chronic, progressive, multi-system condition that primarily 
affects the respiratory, gastrointestinal and reproductive systems.  CF places a substantial 
burden on people with the condition and their families and support systems, who need to 
manage the implications of CF in terms of symptoms, complications and prognosis, and the 
extraordinarily demanding treatment regimen (Abbott, & Hart, 2005).  
It is the most common serious hereditary disease in Caucasians having a birth-
prevalence of 1 in 2,000/2,500 (Macneil, 2016; Feuchtbaum, Carter, Dowray, Currier, & 
Lorey, 2012).  Once seen as a pediatric condition because patients rarely survived into 
adulthood, progress in treatment over the past 20 years means that UK newborns with CF are 
now expected to live into their mid-50s and beyond (Dodge, Lewis, Stanton, & Wilsher, 
2007), with a next generation of treatments based on genetic mutation class promising even 
further advances (MacKenzie et al. 2014; Ratjen et al. 2015).  Despite this, progressive 
disease continues to lead to respiratory failure, prolonged periods of ill-health and reduced 
quality of life before death.  Median age of death in the UK is 31 years (Cystic Fibrosis Trust, 
2018) and maintaining good health requires people with CF to adhere to a time-consuming 
and demanding daily treatment regimen.  One consequence of recent advances in care is that 
the burden of adherence has increased, with patients having to engage daily in a number of 
treatments including chest physiotherapy, enzyme replacement therapy, high-fat intake 
requirements and prophylactic antibiotics, mucolytics and vitamins.  The median time spent 
daily on such treatments has been found to be 108 minutes (Sawicki, Sellers, & Robinson, 
2008).  People with CF also need to adhere to strict infection control guidelines which 
involves impeccable hygiene, avoiding other people with CF and being isolated in single-bed 
rooms when in hospital.  The prevalence and impact of mental health problems on physical 
health outcomes in CF is becoming better understood (Quittner et al. 2014; Quittner et al. 
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2016). People with CF are thought to be at risk of depression and anxiety symptoms 
(Quittner, Goldbeck, et al., 2014) with the former in particular impacting on 5-year survival 
rates (Schechter, Ostrenga, Fink, Barker, & Quittner, 2017). 
Over the last decade, investigations of treatment-specific adherence in CF care have 
shown different rates to different therapies (Quittner et al. 2014), with inhalation therapy 
being of particular interest due to its important role in preventing, eradicating and treating 
lung infection (Bodnár, Mészáros, Oláh, & Ágh, 2016).  Although measuring adherence to 
inhalation therapy has benefitted significantly from Adaptive Aerosol Delivery™ (AAD) 
technology – which electronically records nebulizer use – the complex factors which 
influence the process of actually adhering remain largely elusive (McNamara, McCormack, 
McDonald, Heaf, & Southern, 2009).  Variables known to be important in CF treatment 
adherence include age, beliefs about medication, and characteristics of the treatment (Duff, & 
Latchford, 2010).  In general, maintaining adherence to a treatment regimen over the longer 
term is also dependent on developing habits as part of a daily routine (e.g., Yeh et al. 2018).  
For adolescents, these factors invariably include their parents or caregivers. 
Sub-optimal adherence to CF treatments is the single biggest cause of treatment failure 
in CF (Quittner, Modi, Lemanek, Ievers-Landis, & Rapoff, 2008), and the most important 
factor in the accelerated deterioration in the condition reported in adolescents and young 
adults (Narayanan, Mainz, Gala, Tabori, & Grossoehme, 2017; Osterberg, & Blaschke, 2005).  
Poor adherence is linked to reduced lung-function and poorer health outcomes (Eakin, 
Bilderback, Boyle, Mogayzel, & Riekert, 2011), and associated with increased rates of 
exacerbation and need for intravenous antibiotic treatment (Briesacher et al. 2011; DiMatteo, 
Giordani, Lepper & Corghan, 2002; Arias Lorente, Bousono Garcia, & Diaz Martin, 2008).  
Many young people struggle to assimilate CF therapies into their daily routines and this has 
been reported to adversely affect psychological well-being and health-related quality of life 
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(Sawicki, & Goss, 2015).  The transition to self-management of a long term condition by 
adolescents is a crucial stage, set against a background of shifting psycho-social processes 
(Giarelli, Bernhardt, Mack, & Pyeritz, 2008).  Understanding and improving adherence is one 
of the most important contemporary challenges in CF, particularly since the advent of a new 
generation of treatments promising greatly increased efficacy.  This is even more important  
for children and young people, where establishing good practice in adherence behavior has 
significant implications for later life (Abbott, & Bilton, 2015; Duff, & Oxley, 2016). 
The aim of the current study was to elicit the perspectives of adolescent patients with 
CF and their parents on the process of adhering to inhalation therapy.  It used a qualitative 
methodology enhanced by the provision to patients and parents of accurate adherence data as 
part of the semi-structured interviews.  This innovative approach enabled us to prompt 
memory recall and ground the interviews in reality to open avenues of discussion that would 
not otherwise have been apparent. 
Methods 
Design 
Ethical approval was granted for this study by the regional NHS National Research 
Ethics Service (ref: 11/YH/0284).  Individual, semi-structured, face-to-face interviews were 
conducted with adolescents with CF and one of their parents in order to elicit experiences, 
understandings and perspectives of the process of adhering to inhalation therapy via the I-
nebTM (Profile Pharma, Zambon SpA, Chichester, UK) device.  The I-nebTM is used to take 
routine treatments such as bronchodilators (which make breathing easier) and occasional 
treatments for acute infection (antibiotics); all prescribed inhalation therapy via the I-nebTM 
was a target of interest in this study. 
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The I-nebTM uses vibrating mesh technology and an Adaptive Aerosol DeliveryTM 
(AAD) system to deliver precise doses of aerosol into the inspiratory phase of the respiratory 
cycle.  This technology has resulted in much quicker administration of treatment doses than 
previous types of nebulizer.  Data about each treatment taken (including whether or not the 
dose has been administered fully) is recorded electronically enabling a ‘gold standard’ 
objective measure of adherence to nebulized therapy (McCormack, Southern, & McNamara, 
2012).  Adherence is calculated by dividing the actual number of doses taken by the expected 
(prescribed) doses, alongside the number of taken doses that were fully administered to give 
an overall percentage of adherence which is highly reliable and objective. 
Adolescents were eligible for participation if they were 11–16 years of age, had a 
confirmed diagnosis of CF via sweat testing or CF-causing mutations and had been using the 
I-nebTM device for at least the last 12 months as part of their treatment regimen.  Separate 
participant information sheets were developed for both the adolescent patients and the 
parents.  This provided clear information about the study and invited participation.  The 
parents and the adolescents were asked to sign a joint consent form in order to take part in the 
study.  Participants were excluded if they were not deemed clinically stable (i.e., Forced 
Expiratory Volume in one second [FEV1] <50% in the preceding 12 months). 
Sample 
A convenience sample of six adolescents from two UK regional pediatric CF centers 
(Leeds and Liverpool) were recruited in order of attendance at routine out-patient 
appointments by their physiotherapist, resulting in a sample representative of adolescent 
patients seen in clinic, with variable adherence rates.  They and one of their parents were 
interviewed separately, resulting in a total sample of 12.  Those identified as the primary 
caregiver were invited to take part as we were keen to better understand the impact of this 
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important relationship on the process of adherence to aerosol therapy.  The sample size 
enabled in-depth interviews to be conducted in order to facilitate this aim and to further 
explore participants’ lived experience of aerosol therapy.  The mean age of the adolescent 
participants was 13.2 years and the mean age of the parent participants was 42 years. 
Procedure 
Following recruitment, electronic diary data which is routinely downloaded from the 
I-nebTM at out-patient appointments by a physiotherapist was sent via secure e-mail to the 
chief investigator ahead of the semi-structured interviews.  In order to anchor participants’ 
experiences in real-life examples and prompt recall, part of the semi-structured interview was 
guided by a seven-day retrospective ‘diary’ based on an adapted printout of the electronic data 
downloaded from the I-nebTM device.  This information was presented in an easy-to-
understand table and discussed in addition to more general questions about the process of 
adhering to aerosol therapy.   
Questions specifically relating to the I-nebTM data were incorporated into the interview 
schedule for both the adolescent patients and the parents in order to stimulate recall and 
prompt discussion of factors that may have influenced the process of adherence.  The 
interview schedule enabled a similar structure for the adolescent and parent interviews but 
with a slightly different emphasis depending on the topic being discussed (e.g., “Looking  at  
this  information  here,  were  there  any  days  and  times  that  you  found  it  easier  to  take 
your  aerosol  therapy?” vs. “Looking  at  this  information  here,  were  there  any  days  and  
times  that  you  think  your  child  found  it  easier  to  take  their  aerosol  therapy?”)     
Participants were aware that the I-nebTM data would be used to inform the interview 
and the participant information sheets encouraged typical adherence behavior prior to the 
interviews by reassuring them that we were interested in their experiences of both adhering 
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and not adhering to their aerosol therapy.  As I-nebTM data are commonly discussed with the 
adolescent patients and their parent as part of their routine clinic appointments, it was not 
thought that this would significantly influence adherence behavior prior to the research 
interview.  Indeed, we were expecting similar experiences to those observed in routine clinics 
whereby a range of adherence rates are present regardless of the child and parent being aware 
that the I-nebTM data will be downloaded and discussed.       
The semi-structured interviews were recorded and lasted approximately 90 minutes 
each.  Over 500 pages of interview transcripts were produced and then analyzed separately 
using Grounded Theory Method (GTM). 
Data analysis 
The data analysis process was guided by the model of GTM proposed by Strauss and 
Corbin (1990) and Charmaz (2006).  Analysis progressed from initial generation of open 
codes (whereby the transcripts were analyzed line-by-line with a code assigned to each), to 
refinement of higher order categories (axial coding stage one and two whereby open codes 
were grouped into a series of emerging categories) and finally the identification of core 
categories which became the basis for the theoretical formulation.  Data analysis was 
supported by other techniques commonly used in GTM including constant comparison (by 
which new codes were constantly compared and modified alongside existing ones), memo 
writing (process notes on the analysis), and diagramming (a visual display that helped to 
conceptually map the process of analysis). 
  Efforts to ensure methodological rigor were focused on engaging in regular 
individual and group supervision (which consisted of members conducting qualitative 
research).  Individual and group supervision sessions were facilitated by two senior academics 
who are experienced in using GTM.  Supervision enabled the checking of line-by-line initial 
9 
 
codes, making comments and observations about axial codes and ensuring that the theoretical 
formulation could be further developed and refined.  Minutes of the research supervision 
sessions were kept so as to provide a record of detailed discussions.  This approach enabled 
the maintenance of an “audit trail” which Burns (1989) argues is a major factor in ensuring 
methodological and procedural rigor in qualitative research.   
Results 
Table 1 outlines demographic details of the child-parent dyad participants along with 
information relating to the adolescent child’s aerosol therapy regimen. 
Table 1: Participant demographic information (N=12) 
Participant Gender Parent Aerosolized 
treatment(s) and daily 
dosage prescribed 
Treatments 
taken 
Doses 
administered 
fully 
Overall 7 day 
adherence 
rate (%) 
       
Child 1 
 
Female Mother DNase1 (1 per day) 2 of 7 1 of 2 14.29 
Child 2 
 
Male Mother DNase1 (1 per day) 7 of 7 7 of 7 100 
Child 3 Female Mother DNase1 (1 per day) 5 of 7 3 of 5 42.86 
Child 4 
 
Female Father DNase1 (1 per day) 
Promixin2 (1 per day) 
14 of 14 13 of 14 92.86 
Child 5 Male Mother Colomycin2 (2 per day) 12 of 14 12 of 12 85.71 
Child 6 Male Mother Colomycin2 (1 per day) 
DNase1 (1 per day) 
13 of 14 13 of 13 92.86 
1 bronchodilator; 2 antibiotic 
Analysis of the parent and adolescent data produced a series of initial open codes and 
higher order categories.  Coding parent data produced 436 open codes and 112 higher order 
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categories, further revised to produce a theoretical formulation consisting of 9 core categories, 
and 42 subcategories.  Adolescent data produced 362 open codes and 87 higher order 
categories, revised into 9 core categories, and 37 subcategories.  The theoretical formulations 
for each group were represented visually and were broadly similar, each featuring nine core 
categories and four main processes (interaction with the aerosol therapy; internal cognitive, 
affective and behavioral processes; parent and adolescent interactions and experience of each 
other; the context of adherence), although each group had their own perspectives.  A 
combined theoretical formulation is shown in Figure 1. 
Figure 1: Combined theoretical formulation (INSERT FIGURE 1 HERE) 
Qualitative themes 
Parents and adolescents gave different but overlapping views of the aerosol regimen 
and the context in which adherence takes place.  In particular, beliefs, emotional reactions and 
behavioral strategies connected to adherence were discernible in the accounts of both groups, 
and these interact with the parent and adolescent experience of one another, mediated largely 
by the strength of the relationship.  The themes, example sub-themes and illustrative 
quotations from parent and adolescent perspectives are summarized in Figure 2 and then 
expanded upon further below. 
Figure 2: Summary of main themes and examples of sub-themes, with illustrative quotations 
from parent and adolescent highlighting different viewpoints and perspectives (INSERT 
FIGURE 2 HERE) 
Themes around the therapy 
  The process of adhering to aerosol therapy was experienced as only one part of a 
complex and demanding CF treatment regimen that places significant strains on the parents 
and young patients: 
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It is tough and I think when the doctors are saying you need to do this, this and this, 
they don’t realize the day to day struggle of what it’s really like to live with it.  You 
know it’s alright for them to sit there and say he needs this nebulizer every day, this 
tablet every day, that tablet every day, they’re not dishing them up, administering all 
the medicine. (Parent) 
The emphasis on the lack of immediate feedback (benefit) of the aerosol therapy was 
seen as a problematic barrier by some, but the feedback offered by the interactive features on 
the device itself was often experienced as a positive facilitator to adherence: 
It buzzes and then I keep doing that until it like beeps once more and a smiley face 
comes on the screen. (Child, aged 12) 
Sometimes if I haven’t got the nebs in the right position it makes a little alarm. (Child, 
aged 13) 
The I-nebTM was seen as less cumbersome and easier to use than other aerosol devices, 
which meant that many of the young patients were able to take responsibility for preparing the 
medication themselves.  However, the specific instructions for cleaning and drying the device 
resulted in many of the parents doing this in practice and it was seen as onerous: 
That’s another thing, you have to boil the damn thing once a week, you have to boil it 
for about 10, 15 minutes. (Parent) 
There were mixed views from both parents and young patients on using the data 
downloaded from the I-neb™ as a part of routine clinical practice, with some seeing it as 
motivating and others as punitive: 
I think it does help, like ‘cos you can see what it’s really like, I mean I’ve never 
thought of it like that.  I never really looked at it like this before. (Child, aged 13) 
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The downloaded information?  This is where Big Brother looks at you and points the 
big finger! (Parent) 
The most common theme expressed here concerned the way in which the data was 
communicated by the health care professional involved; with appropriate language (e.g., “I 
wonder if it would be ok to look at the feedback together?”), empathy and tactfulness seen as 
important motivators for adherence. 
Cognitive, affective and behavioral processes of the adolescent and parent 
 The complex way in which salient thoughts and beliefs about aerosol therapy interact 
with feelings concerning adherence were seen as influencing the behavior of both the young 
people and the parents day by day.  Sometimes families used strategies to increase adherence, 
with mixed success.  Many young people, for example, knew about the serious consequences 
of not adhering to aerosol therapy.  Whilst awareness of the consequences generated fear 
which was not pleasant, adolescents acknowledged that it probably encouraged adherence too: 
At the end of the day if I don’t take them I could die because I would become ill and 
that but it’s keeping me alive…but I don’t like doing them. (Child, aged 12) 
Beliefs were not static however – with some adolescents and parents being aware of 
the potential consequences of non-adherence but expressing doubts about effectiveness:  
I don’t feel like it does much but I know like when I don’t take it, I do notice that my 
chest feels a bit worse, but like for a day if I didn’t take it then I wouldn’t notice.  I 
went through a phase of not taking it because I didn’t think it was doing anything. 
(Child, aged 16) 
I can understand why some parents would think ‘stuff it, it’s making no difference’ 
because in some ways I feel like that. (Parent) 
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 The interviews highlighted different perspectives on parent-child interactions related 
to adherence.  Parents reported concern, for example, at the thought of relinquishing control 
as their child grows older; often causing significant anxiety and leading to increased daily 
reminders, and guilt if their child did not adhere.  Adolescents, on the other hand, struggled to 
understand the parents’ perspective; seeing parental frustration as a sign of not being 
understood and this in turn contributed to their own feeling of frustration and a sense of being 
different to others: 
I like to know she’s done it because if she hasn’t done it I worry and again it’s, she’ll 
say I’m a control freak and I probably am a bit but having had all the years where I 
had complete control over her treatments to almost having no control at all now, erm 
yeah I like to remind her, just check in my own mind that she’s done it. (Parent) 
Cos it’s like, no one else understands really.  Like with my nebulizers it’s like I know 
mum thinks it isn’t much to do and I suppose it isn’t but it’s just another thing. (Child, 
aged 14) 
 The social context of adherence was discussed by several adolescents, who 
acknowledged thoughts about some treatments being easier (or less embarrassing) to do in 
front of peers – or family – than others: 
You could go on the trampoline and that, you could do that with a mate but you 
couldn’t take your nebulizer with a friend obviously. (Child, aged 11) 
There was general awareness of a number of daily barriers to adherence (e.g., lack of 
time, feeling upset, tiredness and distractions) but the electronic diary data allowed 
participants to illustrate these with concrete examples: 
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I was really tired and just didn’t do them.  It depends what mood I’m in really.  Erm 
sometimes when I’m tired, erm, or just don’t feel like doing them. (Child, aged 12) 
She wanted to watch ‘I’m a celebrity’ and I told her to get it done. (Parent) 
Parent and adolescent interactions and experience of each other 
 Parents were sensitive to non-adherence, particularly as children took more 
responsibility themselves.  This led to attempts by parents to prompt their child, and feelings 
of guilt and worry if they felt adherence was poor.  Adolescents, on the other hand, generally 
resented parental reminders (often described as nagging) but paradoxically acknowledged that 
they often led to increased adherence: 
I don’t like being reminded but I know that if I don’t get reminded then I won’t do it. 
(Child, aged 16) 
The diary prompted concrete examples of the way in which language based on 
negotiation rather than challenge was more acceptable and felt to be more effective in 
prompting behavior: 
I said ‘while I’m in the shower, you make up your colomycin for me’ so that’s what he 
done. (Parent) 
...after my dinner all my physio and I-neb and everything, after I’ve done all that, I can 
go back on my Xbox for like 10 or 20 minutes. (Child, aged 11) 
Parent accounts suggested that they thought it important to accommodate specific 
treatment preferences, particularly around aerosol therapy, as a way of anticipating and 
managing potential problems and conflict: 
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I think his physio, he’s more inclined not to want to do that than his aerosol therapy 
because he knows that’s only going to take him a very short amount of time. (Parent) 
In fact, the strength of the parent-adolescent relationship had the potential to act as a 
“buffer” and adolescents referred to ways in which practical and emotional support from 
parents had helped facilitate adherence and avoid conflict.  However, the transition of 
responsibility with increasing age was a key theme.  Although adolescents acknowledged this 
and felt that they needed to do more, in general parents continued to provide practical support 
– they ordered the medication and cleaned the device. 
The context of adherence 
 Both groups discussed the way in which daily life influenced adherence – the diary 
prompted comments on the difficulties of attempting to fit multiple tasks into a limited 
amount of time.  Aerosol therapy was seen as one part of a time consuming and burdensome 
treatment regimen.  Some treatments were discussed as being interdependent, particularly 
aerosol therapy and physiotherapy, with the electronic diary data again prompting examples 
of how in practice the two treatments had to be planned so that there was a gap between them:  
It can’t be too close to his nebulizer either erm, if you’re doing his physio it has to be 
at least an hour after his nebulizer. (Parent) 
Particular times and events were seen as problematic, with holidays, school trips and 
sleepovers given as examples, partly because of pragmatic considerations such as cleaning the 
nebulizer.  Parents and adolescents both commented on distractions which could lead to 
treatments being delayed or forgotten, especially social media and video games, and this was 
reinforced through several examples prompted by the electronic diary data: 
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I was probably on my computer, I might have been texting someone.  If I’m on 
Facebook and I see something interesting, I’ll put it down to type something and I’ll 
forget about it. (Child, aged 14) 
In general, both groups agreed that evening was better than morning because it was 
less busy, and weekends and school holidays were worse because there was less structure.  
Interestingly, for some participants busy lives were seen as a barrier to adherence, whereas for 
others, activities were used to increase motivation by acting as a reinforcing activity to be 
engaged in only after adherence.  
Discussion 
 In this study, we qualitatively explored how the process of adhering to aerosol therapy 
in CF was experienced by both adolescent patients and their parent. The analysis revealed a 
complex interaction of cognitive, emotional and behavioral processes around adherence, with 
the parent and adolescent experience of one another at the core, and the parent and child 
relationship mediating the interactions.  The above processes are further influenced by the 
interactions with the aerosol therapy treatment regimen, device characteristics and context in 
which adherence is taking place. 
 Participants were prompted by the electronic diary data downloaded from the I-nebTM 
device which provided a window into their lived experience and enabled rich and open 
accounts of the processes that influence adherence to aerosol therapy treatment.  Parents and 
adolescents often compared aerosol therapy to other forms of treatment, with an internal 
hierarchy of preference often favoring those treatments that were quick and less intrusive.  
Although the overall theoretical formulation was very similar for adolescent and parent, the 
analysis highlighted the way in which the same phenomena could be experienced from 
different viewpoints and provided valuable insight into the process of adherence from both 
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perspectives.  One interesting aspect that we were not adequately able to explore is whether 
the interactions between parent and child vary according to whether they were the same sex – 
i.e., our sample contained two mother-daughter dyads and four mixed dyads (three mother-
son and one father-daughter).  It is interesting to speculate on what difference same sex dyads 
may have made, though recruitment did ask to interview the primary caregiver, and the 
interviews showed that the parents were at least very involved in their child’s care. 
 In this study, we provide further insight into the complex social context in which 
adherence is embedded and to which others have previously alluded (Dziuban, Saab-Abazeed, 
Chaudhry, Streetman, & Nasr, 2010). There is also support for the developmental, 
biopsychosocial model proposed by Barker and Quittner (Barker, & Quittner, 2010) with the 
current study identifying influences on adherence which may be seen as biological (i.e., 
therapy regimens that are dependent on disease management and progression), psychological 
(i.e., cognitive, emotional and behavioral processes alongside specific developmental 
challenges at different stages of adolescence in the parent-child relationship) and social (i.e., 
the environment in which adherence takes place and the demands of everyday life). 
 The results of the current study support and extend the conclusions from previous 
research on adherence in CF (e.g., Barker, & Quittner, 2010; Narayanan et al. 2017).  In 
particular, it has highlighted the complexity involved, and the interactions which have a 
substantial influence on adherence – interactions between the different parts of the treatment 
regimen, interactions between the nebulizer and child and nebulizer and parent, interactions 
between children and their peers, and finally between child and parent.  It has also placed 
adherence behavior in context – the internal context of the beliefs and emotions of the child 
and parent, and the exterior context of the busy and complicated lives led by them.  It would 
appear that these interacting biopsychosocial processes make the prospect of consistent, 100 
% adherence to aerosol therapy very unlikely. 
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 Advances in AAD technology have resulted in devices that are more effective, easier 
to use and better able to provide useful feedback that can both encourage adherence and 
promote appropriate administration technique (e.g., cascading feedback system).  However, 
the benefits of more advanced devices paradoxically create a number of associated issues.  
Ensuring that the device is appropriately maintained and cleaned creates an additional burden 
which was identified as a potential barrier by participants in the current study.  Despite the 
device being much smaller and more portable than the previous generation of nebulizers, the 
negative impact that the above issue had on device portability and associated non-adherence 
was a relevant concern, particularly for the parents who were often tasked with cleaning and 
maintenance.  In addition, some of the participants’ saw the I-nebTM as fragile and expensive 
(and worried about losing or damaging the device) so were reluctant to take it away from 
home. 
 Appropriate stakeholders (i.e., patients, parents, clinicians, policymakers and 
manufacturers) may need to engage in a cost-benefit analysis that acknowledges the benefits 
of continued technological improvements alongside the unintended but associated 
consequences.  In doing so, the rhetoric of continual advancement can be more appropriately 
situated in the context of everyday life. 
There are a number of strengths associated with the current study.  It enabled a 
detailed, more focused exploration of one part of the CF treatment regimen rather than CF 
treatment as a whole, as in much of the previous literature (e.g., George et al. 2010).  It 
enabled both a patient and a parent perspective on adherence to be gained.  The use of the 
electronic diary data was not only novel, but enabled adherence behavior to be explored in 
situ, as close as possible to its actual occurrence, grounded in reality as opposed to 
recollections (Reis, & Gable, 2000).  A common criticism of qualitative methodologies is that 
they can only ever access information that the participant is consciously aware of.  The fact 
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that the electronic diary data provided a prompt to participants about the actual rates of 
adherence and incidents which affected this suggested that the diary helped to bring into 
conscious awareness the multiple influences on adherence.  Finally, the sample size enabled 
us to obtain detailed data on this process from a broad range of perspectives. 
Conclusion 
 In this study, we describe a rich framework within which parents and their adolescent 
children negotiate patterns of adherence, balancing the needs of CF with the needs of 
emerging adulthood, and their competing and changing roles.  Optimizing adherence is a key 
challenge for CF teams and it is essential that the different viewpoints of parents and 
adolescents are appreciated in order to optimize the opportunities for support. 
 There are a number of potential clinical implications arising from the current study.  
Health care professionals should demonstrate a continued overt awareness of the burden 
associated with aerosol therapy as only one part of an already complex, demanding and often 
inter-dependent treatment regimen.  This burden is experienced differently by patients and 
parents and the use of the electronic diary data within routine clinical practice may allow this 
to be explored to enable clearer expectations being established collaboratively.  Where 
increasing the number of aerosolized therapies is a necessity, exploring and advising on how 
the revised regimen may fit into their lives may help to motivate patients and parents, 
particularly where the beliefs in the benefits associated with the aerosol therapy are less 
strong.  Indeed, evaluation strategies to simplify the burden of care has recently been cited as 
the top priority for research in CF care (Rowbotham et al. 2017). 
 The current study highlighted the complexity of adherence behavior, and the influence 
of the treatment (e.g., some are preferred over others), the overall regimen (e.g., treatments 
need to be timed relative to each other), the device (e.g., the I-nebTM is preferred but cleaning 
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is an issue), beliefs (e.g., about efficacy of treatment), emotions (e.g., anxiety about the 
consequences of non-adherence), behaviors (e.g., developing a routine) and the real life 
context (e.g., distractions such as Facebook or computer games).  It also found many 
examples where parent and child had different perspectives on the same phenomena (e.g., the 
necessity of parental reminders or nagging).  The electronic diary proved useful in obtaining 
many of these examples, with several participants commenting that they had forgotten about 
something until prompted by the diary in the interview.  The diary may also therefore prove 
useful in assisting patients and parents in the identification of unhelpful influences on 
adherence and may help to target appropriate support, particularly for those whose 
problematic cognitions (e.g., a parent thinking that the aerosol therapy is not working) and 
emotions (e.g., a parent feeling anxiety and guilt) have the potential to result in less helpful 
behaviors (e.g., excessively reminding or “nagging” their child to take the aerosol therapy) 
that may negatively impact on the parent and child relationship.  The importance of being 
clear with patients and parents that the therapy is an investment in long-term well-being and 
that the cumulative effect of missed doses is significant should be done alongside an empathic 
understanding of the complexities of adherence.  
 There was an emphasis within the current study that adherence to aerosol therapy does 
not exist in a psychosocial vacuum.  The use of the electronic diary data within the semi-
structured interviews enabled a number of lifestyle and environmental influences to be 
illustrated.  Open discussion of these influences (using the electronic diary data appropriately) 
may help to identify specific commitments, times, events or situations which have the 
potential to negatively impact on the process of adhering to aerosol therapy.  In this way the 
CF team can work in partnership with the patient and the parents to support overcoming these 
barriers to adherence. 
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